Ifosfamide-based chemotherapy (AI)

PreclinicalSmall molecule

MM.D. Anderson Cancer Center

Ifosfamide-based chemotherapy (AI) is one of 5 small molecule programs targeting PrEP. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PrepCompleted

PrepPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Prep

#DrugCompanyPhaseTrials

Truvada

Gilead

Phase 2

2 2

Psilocybin

COMPASS Pathways

Phase 1

1 3

Gnrh Agonist

Johnson & Johnson

Preclinical

1 4

Emtricitabine/tenofovir

GSK

Preclinical

1 5

Ifosfamide-based chemotherapy (AI)

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

PrEP1 trial

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Completed·MM.D. Anderson Cancer Center·N/A·NCT01490060·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ifosfamide-based chemotherapy (AI). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ifosfamide-based chemotherapy (AI) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ifosfamide-based chemotherapy (AI). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

Ifosfamide-based chemotherapy (AI)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

PrEP1 trial

References

Drug Info

Quick Facts

Related News